JAK2 and type 1 diabetes mellitus: The baricitinib in new onset type 1 diabetes (BANDIT) trial, will investigate whether the JAK1/JAK2 inhibitor baricitinib, currently used in the treatment of rheumatoid arthritis and alopecia, can facilitate beta-cell survival in individuals with recent-onset (<100 days) T1D (78).